Shopping Cart
Clinical article · Neurology and PRP research
Platelet-Rich Plasma (PRP) in Brain Injury: Current Research and Clinical Limits
Platelet-based preparations are also being investigated in experimental neuroscience. At present, however, this does not amount to an established PRP treatment for injured brain tissue. The key distinction is between cell culture work, animal models and clinical evidence.
Medical note: PRP is not an established standard treatment for traumatic brain injury, stroke or encephalitis. Acute neurological symptoms require immediate emergency assessment.
Define the condition precisely
“Brain injury” covers very different disorders
Traumatic brain injury is caused by external mechanical force. Ischaemic stroke results from impaired blood flow, while intracranial haemorrhage follows rupture of a blood vessel. Encephalitis, by contrast, is inflammation of the brain, for example due to infection or an abnormal immune response.
These conditions differ in cause, acute management, risks and underlying biology. Results from a stroke model cannot automatically be transferred to traumatic brain injury. A spinal cord model likewise does not provide evidence for treating encephalitis.
What is PRP?
PRP is a plasma preparation produced from autologous blood with a platelet concentration that differs from baseline whole blood. Depending on the system, it may also contain varying amounts of leucocytes, erythrocytes and other plasma components.
Why does standardisation matter?
PRP is not a single uniform active substance. Cell counts, activation status, leucocyte content and concentrations of individual signalling proteins may vary substantially between systems, patients and repeated preparations.
Biological plausibility is not proof of clinical efficacy. The presence of growth factors such as VEGF, IGF-1, PDGF or TGF-β does not by itself mean that a PRP preparation repairs injured brain tissue.
Preclinical models
Why are platelet products being studied in neurology?
Research groups are investigating whether platelet-derived components can influence processes relevant after nervous-system injury. These include axonal growth, angiogenesis, immune and glial responses, cell survival and the provision of a temporary biological matrix.
Individual components may have different or even opposing effects. In one frequently cited laboratory study, IGF-1 and VEGF were associated with greater axonal growth. At the same time, neutralising TGF-β1 also increased growth, suggesting that this pathway had an inhibitory component in the model examined.
Organ culture
Axonal growth in a brain–spinal cord coculture
Human PRP was added to cultured rat tissue. Greater axonal growth was observed. No patients were treated and no functional recovery in humans was measured.
Animal stroke model
Platelet lysate after ischaemia
In rats, platelet lysate was administered directly into the cerebral ventricles. Lysate is not the same as conventional PRP, and both the route of administration and the model were highly experimental.
Tissue engineering
PRP scaffold with stromal cells
After severe experimental traumatic brain injury, a PRP scaffold combined with mesenchymal stromal cells was surgically implanted into a lesion. This was a combination treatment studied in rats.
Interpret studies correctly
Preclinical research is not the same as clinical evidence
Cell cultures and animal models are useful for studying mechanisms. Many promising preclinical approaches, however, do not translate successfully to people. Differences in anatomy, immune response, injury pattern, dose and route of administration are among the reasons.
| Research model | Material studied | Model | Main limitation |
|---|---|---|---|
| Brain–spinal cord coculture | Human PRP | Rat tissue in the laboratory | No treatment of a living patient |
| Experimental stroke | Platelet lysate | Rats | Lysate cannot be equated with conventional PRP |
| Severe traumatic brain injury | PRP scaffold and stromal cells | Rats | Combination therapy with surgical implantation |
| Peripheral nerve and spinal cord models | Different PRP formulations | Predominantly animal models | Not directly transferable to human brain tissue |
Clinical evidence
Is there clinical evidence for PRP in injured brain tissue?
The available literature does not provide robust randomised clinical evidence that PRP regenerates injured brain tissue in humans or reliably improves neurological outcomes after traumatic brain injury.
A pilot study published in 2024 investigated PRP for post-traumatic occipital neuralgia after concussion. The preparation was injected around a peripheral occipital nerve to address headache. The study did not investigate regeneration of brain tissue.
PRP is also absent as an established neuroregenerative therapy from guidelines on the management of head injury and severe traumatic brain injury. Their priorities include emergency assessment, imaging, airway and circulatory support, neurological monitoring, management of intracranial pressure and, where required, neurosurgical intervention.
No established standard therapy
PRP is currently not an established standard treatment for traumatic brain injury, stroke, encephalitis, hypoxic brain injury or neurodegenerative disease. Experimental findings must not be presented as a treatment recommendation or as evidence that the brain can be “repaired”.
What about intranasal PRP or a combination with insulin?
Intranasal insulin is being studied as a separate experimental approach in several neurological settings. Preclinical traumatic brain injury studies tested insulin without PRP and reported changes in selected memory, inflammatory or lesion parameters.
There is no adequate evidence for an established clinical combination of intranasal PRP and insulin for traumatic brain injury or encephalitis. Studies in other indications, such as olfactory dysfunction, cannot be transferred to injured brain tissue.
Safety and professional responsibility
Autologous does not mean risk-free
PRP is prepared from the patient’s own blood. This avoids certain risks associated with foreign biological materials, but autologous origin does not automatically make either the preparation process or every conceivable application safe.
1
PreparationSterility, prevention of mix-ups, cellular composition and traceability must be controlled.
2
Site of administrationA central nervous system or intracranial procedure is not comparable with an injection into skin, tendon or joint.
3
Patient factorsCoagulation status, concomitant medication, infection and the neurological diagnosis influence risk.
4
Product characterisationWithout precise data on cell content, activation and volume, studies and preparations are only partly comparable.
Direct administration into brain tissue, cerebral ventricles or a lesion would be highly invasive. Its safety cannot be inferred from experience with established peripheral PRP applications.
Unanswered research questions
What would need to be clarified before clinical use?
Which preparation is actually being studied?
PRP, platelet lysate, secretome, extracellular vesicles and PRP fibrin scaffolds are different biological product groups.
How is the final product characterised?
At minimum, studies would need to report platelet count, leucocytes, residual erythrocytes, activation, volume and relevant signalling proteins.
Which route of administration could be acceptable?
Local application to brain tissue poses fundamentally different requirements from a peripheral or superficial injection.
Which phase of disease is being studied?
Acute trauma, chronic sequelae, stroke and encephalitis follow different biological time courses.
Which clinical outcomes matter?
Relevant outcomes would include survival, neurological function, cognition, independence, quality of life and long-term safety.
How can comparability be achieved?
The marked variability of PRP preparations makes detailed documentation and classification of the final product essential.
Clinical interpretation
What can be concluded responsibly?
Platelets and platelet-derived preparations are a relevant field of experimental neuroscience. Laboratory and animal studies suggest that certain products may influence processes such as axonal growth, angiogenesis or cell survival.
These findings concern very different materials, models and routes of administration. Robust clinical evidence for the efficacy and safety of PRP treatment of injured human brain tissue is currently lacking.
Suspected acute brain injury or encephalitis requires immediate neurological or emergency medical care. A PRP procedure must not replace guideline-based diagnosis, acute treatment or rehabilitation.
Technical information on prpmed.de
Further professional reading
The following internal pages address technical and organisational aspects of PRP preparation. They do not constitute a recommendation for neurological use.
Common questions
FAQ on PRP and brain injury
Can PRP regenerate damaged brain tissue?
This has not been demonstrated clinically. Laboratory and animal studies show individual biological effects, but do not prove that PRP restores lost or damaged brain tissue in humans.
Are there PRP treatments after traumatic brain injury?
PRP is not part of established guideline-based treatment for traumatic brain injury. Research mainly involves animal models or combinations of platelet products, scaffolds and cell therapies.
Can PRP be used after concussion?
A small pilot study investigated PRP for post-traumatic irritation of the greater occipital nerve. It addressed a peripheral source of headache, not the concussion or brain tissue itself.
Is platelet lysate the same as PRP?
No. In platelet lysate, platelets are disrupted and intracellular components are released. Conventional PRP generally contains intact platelets in plasma. Their composition and biological properties differ.
Is PRP used for encephalitis?
There is no established clinical evidence for this use. Encephalitis requires urgent diagnosis and cause-specific medical treatment.
Is intranasal PRP with insulin scientifically established?
Not for brain injury. Intranasal insulin and intranasal PRP approaches are studied in different experimental settings, but this does not establish a combination treatment for traumatic brain injury.
Why can animal studies not be transferred directly to humans?
Animal models reproduce only selected aspects of human disease. Anatomy, immune response, injury pattern, timing and route of administration often differ substantially.
Is PRP risk-free because it uses the patient’s own blood?
No. Autologous origin reduces certain incompatibility risks but does not eliminate risks related to preparation, contamination, incorrect use or invasive procedures.
Evidence base
Scientific sources used
- Takeuchi et al.: Human platelet-rich plasma promotes axon growth in brain-spinal cord coculture. Used for the experimental axonal growth model and the roles of IGF-1, VEGF and TGF-β1.
- Hayon et al.: Platelet lysates after experimental stroke. Used to classify preclinical findings on angiogenesis, neurogenesis and neuroprotection.
- Bonilla Horcajo et al.: PRP-derived scaffold and mesenchymal stromal cells after severe traumatic brain injury. Used for the tissue-engineering animal model.
- Scientific paper on the variability of PRP products. Used for differences between preparation systems and products.
- Pilot study of PRP for post-traumatic occipital neuralgia. Used to distinguish peripheral nerve treatment from treatment of the brain.
- Brain Trauma Foundation: Guidelines for the Management of Severe TBI. Used to classify guideline-based acute management.
- NICE: Head injury – assessment and early management. Used for the clinical definition and early management of head injury.
- NHS: Encephalitis. Used to distinguish encephalitis from traumatic brain injury.